Non-Hodgkins Lymphoma Clinical Trial
Official title:
Phase I-II Non-Randomized Study of Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Indolent Non Hodgkin Lymphoma
The purpose of this study is to investigate the ability to combine a radioactive medication directly targeted against lymphoma cells with the immune effects of an allogeneic blood stem cell transplant.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 2012 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: Patients must have/be 1. Age 18 to 65 years. Patients between age 66 and 69 may be enrolled if judged to be in excellent physical condition as per treating physician and study investigator and based on institutional practice. 2. Diagnosis of Non-Hodgkin lymphoma, follicular, marginal zone, small lymphocytic lymphoma, mantle cell lymphoma or transformed from an indolent NHL to aggressive histology disease lymphoma as defined by the World Health Organization. 3. Disease relapsed after, refractory or failing to achieve a PR after two or more cycles of intensive salvage chemotherapy (R-ESHAP or other) or disease relapsed after autologous stem cell transplantation. Poor partial response is defined as less than 50% reduction of tumor size. Salvage chemotherapy has to be administered after either 1st, 2nd or 3rd relapse 4. Disease expressing the CD 20 antigen 5. ECOG performance status 0-2 6. Judged to be able to tolerate NST and Zevalin treatment based on institutional criteria. 7. Signed written informed consent 8. At least one fully HLA matched sibling without evident contraindications to the donation procedures and willing to sign consent for donation Exclusion Criteria: Patients must not have/be 1. Abnormal renal function (creatinine > 1.5 x upper limit of normal (ULN) 2. Abnormal hepatic function (bilirubin > 2 x ULN, ALT/AST>2x ULN) 3. Cardiac ejection fraction <40% and/or other significant cardiac compromise 4. Severe defects in pulmonary function tests or receiving continuous oxygen 5. Severe concurrent illness, such as symptomatic congestive heart failure, severe arrhythmias, uncontrolled hypertension, diabetes, severe neurologic or psychiatric disorder or known HIV positive 6. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1) that may impact on patients life expectancy or any cancer curatively treated < 3 years prior to study entry. 7. History of prior allogeneic bone marrow transplant 8. Evidence of active hepatitis B or C infection or positivity for hepatitis-B surface antigen 9. Known type 1 hypersensitivity or anaphylactic proteins to any component of the Zevalin therapy or a history or presence of human anti-mouse antibodies (HAMA) 10. A female patient who is pregnant or breast feeding and an adult of reproductive potential who is not employing an effective method of birth control during the study. 11. CNS lymphoma 12. Ongoing confirmed or suspected significant infection 13. Prior treatment with radioimmunotherapy 14. Other condition preventing participation in standard NST 15. No fully matched sibling donor |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Hopital Maisonneuve-Rosemont | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Maisonneuve-Rosemont Hospital | Bayer |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Engraftment, chimerism, transplant related toxicity, acute and chronic GVHD | one year | Yes | |
Secondary | Overall response rate, overall and disease free survival | 360 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04240704 -
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
|
Phase 1 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT00764829 -
Blood Samples to Evaluate Biomarkers of Donor Chimerism
|
N/A | |
Completed |
NCT00726934 -
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
|
N/A | |
Completed |
NCT01517581 -
Brown Fat Activity and White Fat Accumulation
|
N/A | |
Completed |
NCT00193505 -
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
|
Phase 2 | |
Terminated |
NCT01744912 -
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
|
Phase 1 | |
Terminated |
NCT01500161 -
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
|
Phase 2 | |
Active, not recruiting |
NCT03533283 -
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00001379 -
Treatment and Natural History Study of Lymphomatoid Granulomatosis
|
Phase 2 | |
Completed |
NCT00574730 -
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma
|
N/A | |
Completed |
NCT00901225 -
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
|
Phase 2 | |
Terminated |
NCT01598025 -
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
|
N/A | |
Terminated |
NCT01326728 -
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
|
||
Completed |
NCT01290549 -
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
|
Phase 1 | |
Completed |
NCT00807677 -
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT00837200 -
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
|
Phase 2 | |
Terminated |
NCT00054834 -
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
|
Phase 1 | |
Terminated |
NCT00003500 -
Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT02099266 -
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
|
N/A |